Skip to content
Screener

Upstream Bio, Inc. UPB Q3 2025 earnings

Reported November 5, 2025 · Before market open

Revenue$683.0KBeat by $161.4K
EPS-$0.63Beat by $0.15
Revenue estimate$521.6K
EPS estimate-$0.78

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$522.5K
EPS estimate-$0.73

Financials

Q3 2025

Income statement

See full
Revenue$683.0K+12.5%
Operating income-$37.8M-100%
Net income-$33.7M-111%
EPS (diluted)-$0.63+90.9%

Balance sheet

See full
Cash & equivalents$72.2M+119%
Total debt$1.4M-26.9%
Total equity$378.6M+336%
Total assets$391.2M+68.1%

Cash flow

See full
Operating cash flow-$22.2M-59.3%
CapEx$64.0K—
Free cash flow-$22.3M—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.01B—
Enterprise value$943.29M—
P/S362.3×—

Profitability

See full
Operating margin-5,020.1%+10,886pp
Net margin-4,366.8%+18,012pp

Returns & leverage

See full
Debt / equity0×—
Current ratio32.7×+11.8×

FAQ

When did Upstream Bio, Inc. report Q3 2025 earnings?
Upstream Bio, Inc. (UPB) reported Q3 2025 earnings on November 5, 2025 before market open.
What were Upstream Bio, Inc.'s Q3 2025 revenue and EPS?
Upstream Bio, Inc. reported revenue of $683.0K and eps of $-0.63 for Q3 2025.
Did Upstream Bio, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $521.6K by $161.4K. EPS beat the consensus estimate of $-0.78 by $0.15.
How did Upstream Bio, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 12.5% from $607.0K a year earlier and eps grew 90.9% from $-6.96.
Where can I find Upstream Bio, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-265705) and the 10-Q periodic report (0001193125-25-265713) directly on SEC EDGAR. The filing index links above go to sec.gov.